Aurgalys Team
Selected Customers
Home
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]
 

November 12th, 2015: Aurgalys releases an analyst report on OSE Pharma [Euronext:OSE]

novembre 12, 2015

Paris-Evry, France, November 12th, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, issued an analyst report on OSE Pharma

« With the authorization from 7 European countries, OSE Pharma is now ready to begin the Phase III trial in NSCLC for its lead drug candidate Tedopi. This drug candidate is an immunotherapy against cancer that has already demonstrated efficacy in phase II. Tedopi’s Phase III results are expected in 2018. »

You can download analyst report (in English) on the following link:

 

Comments are closed.